Dr. Joseph Maroon Discusses Possible Breakthrough For Prostate Cancer Treatment

April 2024 – Dr. Joseph Maroon, Neurosurgeon and Wellness Expert recently discussed SYNC-T, a novel, minimally invasive immunotherapeutic approach to treat metastatic solid tumors, at the Norton Neuroscience Institute in Kentucky.  Initial Phase 1 data for this new therapy was recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego on April 7th.

The AACR is one of the largest cancer research conferences in the world, with over 22,000 attendees and more than 10,000 abstracts submitted for inclusion in the meeting.  The SYNC-T abstract was selected to be presented orally at the meeting, which is a very high honor as less than 1% of the abstracts are awarded this opportunity.  Dr. Charles Link, a Medical Oncologist and Executive Chairman of Syncromune, presented interim SYNC-T SV-102 data from the Phase 1 trial for the treatment of metastatic castrate-resistant prostate cancer.

In ‘News and Events’ below you can learn more about the trial in a press release from the AACR entitled  “A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer.”  In addition, you can watch a 3-minute animation HERE that explains how the SYNC-T Therapy works.

Images provided by Syncromune Presented at the AACR Annual Meeting April 7, 2024

The above pre- and post-therapy PSMA PET/CT scans are from a subject in the trial that presented with over 50 metastatic bone lesions throughout his spine and pelvis.  After seven treatment cycles of SYNC-T SV-102, the subject had complete resolution of all the bone metastases, achieving a complete response.

“It is one of the most dramatic results I have seen in 50 years of Neurosurgery, and one of three patients presented by Dr. Link at the Conference, with similar complete remission (right image) after the treatment”, per Dr. Maroon.

Jason Williams, an interventional oncologist who pioneered the development of this new therapy is also having considerable success using the new treatment approach with other solid tumors including intractable metastatic pancreatic, breast and lung cancers as part of other investigational trials.

Syncromune plans to file an IND within the next few months and upon FDA approval will begin a Phase 1b/2 trial of SYNC-T SV-102 for metastatic castrate-resistant prostate cancer in the second half of 2024. Five centers in the U.S. will be selected, with Weill Cornell in New York as the lead site.

DISCLAIMER – Dr. Joseph Maroon is on the board of directors of Syncromune. Currently the SYNC-T Therapy is investigational and has not been determined safe and effective by the U.S. Food and Drug Administration (FDA).

You can visit www.syncromune.com to learn more.